FDA Approved Products

1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
Active:Lifecycle: PeakClear all
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
clindamycin phosphate
Peak
Baxter
INTRAVENOUS · SOLUTION
the following in adultPneumococci+32
2017
NDA
30/100
CODEINE SULFATE
codeine sulfate
Peak
Hikma
ORAL · SOLUTION
mild to moderate painwhere treatment with an opioid is appropriate+1
2011
NDA
30/100
COLPREP KIT
magnesium sulfate; potassium sulfate; sodium sulfate
Peak
R-Pharm US
ORAL · POWDER
2016
NDA
30/100
CONJUPRI
levamlodipine
Peak
ORAL · TABLET
hypertension in adultsolder+3
2019
SMNDA
30/100
CORPHEDRA
ephedrine sulfate
Peak
Pfizer
INTRAVENOUS · SOLUTION
clinically important hypotension occurring in the setting of anesthesia
2017
NDA
30/100
COSOPT PF
dorzolamide hydrochloride and timolol maleate
Peak
Thea Pharma
OPHTHALMIC · SOLUTION/DROPS
elevated intraocular pressure (IOP) in patients with open-angle glaucomaocular hypertension+2
2012
NDA
30/100
CYCLOPHOSPHAMIDE
cyclophosphamide
Peak
Hikma
ORAL · CAPSULE
biopsy proven minimal change nephrotic syndrome in pediatric patientslymphoma+2
2013
NDA
30/100
CYSTADROPS
cysteamine hydrochloride
Peak
Recordati
OPHTHALMIC · SOLUTION/DROPS
corneal cystine crystal deposits in adultschildren with cystinosis
2020
NDA
30/100
CYSTARAN
cysteamine hydrochloride
Peak
Leadiant Biosciences
OPHTHALMIC · SOLUTION/DROPS
corneal cystine crystal accumulation in patients with cystinosis
2012
NDA
30/100
DAPTOMYCIN
daptomycin
Peak
Hikma
INTRAVENOUS · POWDER
pneumonialeft-sided infective endocarditis due to S+13
2017
NDA
30/100
DAPTOMYCIN
daptomycin
Peak
Sagent Pharmaceuticals
INTRAVENOUS · POWDER
pneumonialeft-sided infective endocarditis due to S+13
2017
NDA
30/100
DARTISLA ODT
glycopyrrolate
Peak
Bridge Therapeutics
ORAL · TABLET, ORALLY DISINTEGRATING
symptoms of a peptic ulcer
2021
NDA
30/100
DECITABINE
decitabine
Peak
Fosun Pharma
INTRAVENOUS · POWDER
untreatedde novo+10
2014
NDA
30/100
DELZICOL
mesalamine
Peak
AbbVie
ORAL · CAPSULE, DELAYED RELEASE
mildly to moderately active ulcerative colitis in patients 12 years of ageolder+1
2013
NDA
30/100
DESVENLAFAXINE
desvenlafaxine
Peak
ORAL · TABLET, EXTENDED RELEASE
2013
NDA
30/100
DESVENLAFAXINE
desvenlafaxine fumarate
Peak
Teva
ORAL · TABLET, EXTENDED RELEASE
2013
NDA
30/100
DESVENLAFAXINE
desvenlafaxine fumarate
Peak
Fosun Pharma
ORAL · TABLET, EXTENDED RELEASE
2014
NDA
30/100
DIACOMIT
stiripentol
Peak
Biocodex
ORAL · FOR SUSPENSION
seizures associated with Dravet syndrome in patients taking clobazamolder+2
2018
NDA
30/100
DIACOMIT
stiripentol
Peak
Biocodex
ORAL · CAPSULE
seizures associated with Dravet syndrome in patients taking clobazamolder+2
2018
NDA
30/100
DICLEGIS
doxylamine succinate and pyridoxine hydrochloride
Peak
Duchesnay
ORAL · TABLET, DELAYED RELEASE
nauseavomiting of pregnancy in women
2013
NDA
30/100
DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%
diltiazem hydrochloride
Peak
INTRAVENOUS · SOLUTION
hypertensionchronic stable angina+1
2021
NDA
30/100
DOCETAXEL
docetaxel
Peak
Pfizer
INJECTION · INJECTABLE
metastatic breast cancer after failure of prior chemotherapymetastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy+6
2014
NDA
30/100
DOCETAXEL
docetaxel
Peak
Teva
INJECTION · INJECTABLE
metastatic breast cancer after failure of prior chemotherapymetastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy+6
2013
NDA
30/100
DOCETAXEL
docetaxel
Peak
INJECTION · INJECTABLE
metastatic breast cancer after failure of prior chemotherapymetastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy+6
2012
NDA
30/100
← PreviousPage 4 of 55Next →